Anti-Mullerian hormone: is it a crystal ball for predicting ovarian ageing?

Justine Loh, Abha Maheshwari

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Several studies have demonstrated that anti-Mu¨llerian hormone (AMH) is a better marker of ovarian reserve than age, basal
FSH, estradiol and inhibin. AMH is very good in (i) predicting both over- and poor-response in the controlled ovarian stimulation environment,
(ii) determining the most appropriate stimulation regimen and (iii) pre-treatment counselling for couples to make an appropriate and informed
choice. Recent reports are exploring the use of AMH in various other indications, including (i) predicting long-term fertility and guiding how long
a woman can delay childbearing without facing the risk of reduced ovarian reserve, (ii) predicting the age of menopause, (iii) prediction of ovarian
ageing in women prior to or following chemotherapy, (iv) prediction of long-term fertility following ovarian surgery and (v) screening for polycystic
ovaries. However, widespread use of AMH for indications not proved by evidence-based medicine can lead to either false reassurance or
distress, leading to unnecessary medical interventions . It also has huge implications for costs.We evaluated the evidence basis for using AMH
for various indications to decide how justified it is to promote AMH as a crystal ball, until more evidence is available.
Original languageEnglish
Pages (from-to)2925-2932
Number of pages8
JournalHuman Reproduction
Volume26
Issue number11
Early online date16 Aug 2011
DOIs
Publication statusPublished - 2011

Fingerprint

Anti-Mullerian Hormone
Fertility
Inhibins
Ovulation Induction
Evidence-Based Medicine
Menopause
Counseling
Estradiol
Costs and Cost Analysis
Drug Therapy

Keywords

  • AMH
  • screening test
  • ovarian ageing
  • ovarian reserve

Cite this

Anti-Mullerian hormone : is it a crystal ball for predicting ovarian ageing? / Loh, Justine; Maheshwari, Abha.

In: Human Reproduction, Vol. 26, No. 11, 2011, p. 2925-2932.

Research output: Contribution to journalArticle

@article{2a6998bb2e484106aa83be65a38fe989,
title = "Anti-Mullerian hormone: is it a crystal ball for predicting ovarian ageing?",
abstract = "Several studies have demonstrated that anti-Mu¨llerian hormone (AMH) is a better marker of ovarian reserve than age, basal FSH, estradiol and inhibin. AMH is very good in (i) predicting both over- and poor-response in the controlled ovarian stimulation environment, (ii) determining the most appropriate stimulation regimen and (iii) pre-treatment counselling for couples to make an appropriate and informed choice. Recent reports are exploring the use of AMH in various other indications, including (i) predicting long-term fertility and guiding how long a woman can delay childbearing without facing the risk of reduced ovarian reserve, (ii) predicting the age of menopause, (iii) prediction of ovarian ageing in women prior to or following chemotherapy, (iv) prediction of long-term fertility following ovarian surgery and (v) screening for polycystic ovaries. However, widespread use of AMH for indications not proved by evidence-based medicine can lead to either false reassurance or distress, leading to unnecessary medical interventions . It also has huge implications for costs.We evaluated the evidence basis for using AMH for various indications to decide how justified it is to promote AMH as a crystal ball, until more evidence is available.",
keywords = "AMH, screening test, ovarian ageing, ovarian reserve",
author = "Justine Loh and Abha Maheshwari",
year = "2011",
doi = "10.1093/humrep/der271",
language = "English",
volume = "26",
pages = "2925--2932",
journal = "Human Reproduction",
issn = "0268-1161",
publisher = "OXFORD UNIV PRESS",
number = "11",

}

TY - JOUR

T1 - Anti-Mullerian hormone

T2 - is it a crystal ball for predicting ovarian ageing?

AU - Loh, Justine

AU - Maheshwari, Abha

PY - 2011

Y1 - 2011

N2 - Several studies have demonstrated that anti-Mu¨llerian hormone (AMH) is a better marker of ovarian reserve than age, basal FSH, estradiol and inhibin. AMH is very good in (i) predicting both over- and poor-response in the controlled ovarian stimulation environment, (ii) determining the most appropriate stimulation regimen and (iii) pre-treatment counselling for couples to make an appropriate and informed choice. Recent reports are exploring the use of AMH in various other indications, including (i) predicting long-term fertility and guiding how long a woman can delay childbearing without facing the risk of reduced ovarian reserve, (ii) predicting the age of menopause, (iii) prediction of ovarian ageing in women prior to or following chemotherapy, (iv) prediction of long-term fertility following ovarian surgery and (v) screening for polycystic ovaries. However, widespread use of AMH for indications not proved by evidence-based medicine can lead to either false reassurance or distress, leading to unnecessary medical interventions . It also has huge implications for costs.We evaluated the evidence basis for using AMH for various indications to decide how justified it is to promote AMH as a crystal ball, until more evidence is available.

AB - Several studies have demonstrated that anti-Mu¨llerian hormone (AMH) is a better marker of ovarian reserve than age, basal FSH, estradiol and inhibin. AMH is very good in (i) predicting both over- and poor-response in the controlled ovarian stimulation environment, (ii) determining the most appropriate stimulation regimen and (iii) pre-treatment counselling for couples to make an appropriate and informed choice. Recent reports are exploring the use of AMH in various other indications, including (i) predicting long-term fertility and guiding how long a woman can delay childbearing without facing the risk of reduced ovarian reserve, (ii) predicting the age of menopause, (iii) prediction of ovarian ageing in women prior to or following chemotherapy, (iv) prediction of long-term fertility following ovarian surgery and (v) screening for polycystic ovaries. However, widespread use of AMH for indications not proved by evidence-based medicine can lead to either false reassurance or distress, leading to unnecessary medical interventions . It also has huge implications for costs.We evaluated the evidence basis for using AMH for various indications to decide how justified it is to promote AMH as a crystal ball, until more evidence is available.

KW - AMH

KW - screening test

KW - ovarian ageing

KW - ovarian reserve

U2 - 10.1093/humrep/der271

DO - 10.1093/humrep/der271

M3 - Article

VL - 26

SP - 2925

EP - 2932

JO - Human Reproduction

JF - Human Reproduction

SN - 0268-1161

IS - 11

ER -